Payment overview · 2025
General Payments
$428.99
18 reported records · 9 companies
Healthcare provider profile · identity verified
Shameer B Abrahim, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1255525945
Verified facts
What the public records show
CMS Open Payments records show Shameer B Abrahim, MD received $428.99 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 52.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $224.19 | 52.3% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.56 | 11.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.31 | 8.5% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $27.07 | 6.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.95 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.62 | 6.0% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.65 | 3.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.64 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.00 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $428.99 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $166.24 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.95 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.56 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.56 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 240 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
240 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 632 | 175 |
| Atorvastatin Calcium | Atorvastatin Calcium | 620 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 538 | 163 |
| Losartan Potassium | Losartan Potassium | 452 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 396 | 87 |
| Trazodone Hcl | Trazodone Hcl | 297 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 284 | 91 |
| Metformin Hcl | Metformin Hcl | 278 | 85 |
| Gabapentin | Gabapentin | 277 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 87 |
| Lisinopril | Lisinopril | 246 | 70 |
| Ozempic | Semaglutide | 240 | 41 |
| Tramadol Hcl | Tramadol Hcl | 231 | 53 |
| Omeprazole | Omeprazole | 226 | 71 |
| Sertraline Hcl | Sertraline Hcl | 182 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 46 |
| Alendronate Sodium | Alendronate Sodium | 139 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 39 |
| Furosemide | Furosemide | 132 | 42 |
| Pregabalin | Pregabalin | 131 | 24 |
| Allopurinol | Allopurinol | 125 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 41 |
| Carvedilol | Carvedilol | 124 | 41 |
| Clonazepam | Clonazepam | 123 | 22 |
| Celecoxib | Celecoxib | 120 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 16 |
| Farxiga | Dapagliflozin Propanediol | 114 | 26 |
| Meloxicam | Meloxicam | 114 | 40 |
| Potassium Chloride | Potassium Chloride | 114 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 31 |
| Alprazolam | Alprazolam | 106 | 19 |
| Simvastatin | Simvastatin | 102 | 26 |
| Famotidine | Famotidine | 95 | 37 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 23 |
| Mounjaro | Tirzepatide | 89 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 23 |
| Temazepam | Temazepam | 80 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 16 |
| Montelukast Sodium | Montelukast Sodium | 78 | 20 |
| Eliquis | Apixaban | 77 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 30 |
| Linzess | Linaclotide | 69 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 18 |
| Ezetimibe | Ezetimibe | 67 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 34 |
| Lorazepam | Lorazepam | 63 | 13 |
| Synthroid | Levothyroxine Sodium | 63 | 11 |
| Buspirone Hcl | Buspirone Hcl | 62 | 21 |
| Bupropion Xl | Bupropion Hcl | 60 | 19 |
| Glimepiride | Glimepiride | 60 | 20 |
| Metformin Hcl Er | Metformin Hcl | 60 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 17 |
| Jardiance | Empagliflozin | 58 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 14 |
| Irbesartan | Irbesartan | 52 | 14 |
| Azithromycin | Azithromycin | 51 | 34 |
| Atenolol | Atenolol | 49 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 14 |
| Methylprednisolone | Methylprednisolone | 48 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Mirtazapine | Mirtazapine | 46 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 45 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 14 |
| Clonidine Hcl | Clonidine Hcl | 39 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Nifedipine Er | Nifedipine | 37 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Topiramate | Topiramate | 34 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Torsemide | Torsemide | 29 | 12 |
| Baclofen | Baclofen | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 11 |
| Glipizide | Glipizide | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Repaglinide | Repaglinide | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 14 |
| Prednisone | Prednisone | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Wegovy | Semaglutide | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $428.99 · 18 records | Novo Nordisk Inc | Cologuard Collection Kit, FARXIGA, IBSRELA, INJECTAFER, MOUNJARO, Omnipod, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error